WHO and Eli Lilly warn patients against falling prey to fake versions of popular weight loss drugs, ET HealthWorld

WHO and Eli Lilly warn patients against falling prey to fake versions of popular weight loss drugs, ET HealthWorld


111152432

GENEVA: The World Health Organization and drugmaker Eli Lilly & Co are warning people to be wary of counterfeit versions of popular weight loss and diabetes drugs. The WHO said on Thursday it had received numerous reports of counterfeit semaglutide — the active ingredient in Novo Nordisk's Wegovy and Ozempic — in all geographic regions of the world since 2022.

Lilly said in an open letter that it was “deeply concerned” about rising online sales and social media posts featuring counterfeit or adulterated versions of tirzepatide, the active ingredient behind its drugs Monjaro and Zepbound.

The Indianapolis-based company said it is the only legal supplier of these drugs, and that it does not make tirzepatide available to compounding pharmacies, wellness centers or online retailers.

Lilly said counterfeit versions of its drugs that are often advertised or sold online are never safe to use.

Novo Nordisk has previously issued similar warnings about its drugs.

WHO said patients can protect themselves by purchasing medicines from licensed physicians. Patients should also avoid buying medicines from unfamiliar sources, the agency said.

Lilly said none of the products marketed under the name tirzepatide, not Moanzaro or Zepabound, are made by the drugmaker or have been approved by the U.S. Food and Drug Administration. (AP)

  • Published on June 21, 2024, 06:08 AM IST

Join a community of 2M+ industry professionals

Subscribe to our newsletter to get the latest information and analysis.

Download ETHealthworld App

  • Get realtime updates
  • Save your favourite articles

icon g play

icon app store


Scan to download the app
health barcode



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks